Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Gene “Toggle” Regenerates Injured Heart Cells

By BiotechDaily International staff writers
Posted on 08 May 2012
For the first time, researchers have transformed scar tissue that grows after a heart attack into regenerated heart muscle using microRNAs, according to new lab animal research. If validated in human studies, this finding could help prevent heart failure after a heart attack and applied to other types of tissue regeneration.

The study’s findings were reported online before print April 26, 2012, in Circulation Research, an American Heart Association journal. After a heart attack, heart muscle does not effortlessly regenerate and it accumulates scar tissue, comprised of cells called fibroblasts--increasing risk for heart failure.

“Researchers have tried various approaches, including the use of stem cells, to regenerate damaged heart muscle tissue,” said Victor J. Dzau, MD, the study’s senior author and a professor of medicine at Duke University Medical Center (Durham, NC, USA). “This is the first study to use microRNA, which are small molecules that control gene expression, to reprogram fibroblasts into heart muscle cells. We have not only shown evidence of this tissue regeneration in cell cultures, but also in mice.”

Using microRNA is simpler than many other tissue-regenerating approaches, according to Dr. Dzau, who is also chancellor for health affairs at Duke University. For example, stem cells are not easy to work with and have ethical issues surrounding their use, he noted. “This research represents a major advance in regenerative medicine overcoming the difficulties encountered with stem cells, and may be applied to other conditions of tissue damage such as stroke and spinal cord injury.”

Dr. Dzau’s team identified a combination of three microRNA types that convert fibroblasts to muscle cells. In the next phase of research, the researchers will assess whether microRNAs repair damaged hearts in larger animals and improve heart function. If those studies prove safe and effective, they will begin human studies. “If everything comes to fruition, I think we will see this as a therapy in the next decade,” Dr. Dzau said. “Conceivably, we’ll use it to regenerate hearts damaged by heart attacks, avoiding heart failure and saving lives.”

Related Links:

Duke University Medical Center




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.